Drug Type AAV based gene therapy |
Synonyms LX 103, LX103 |
Target |
Action modulators |
Mechanism XLRS1 modulators(Retinoschisin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinoschisis | Clinical | China | 13 Dec 2022 |